Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients

Liver International

Volumn 31, Issue 1, 2011, Pages 36-41

  Mangia, Alessandra ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

IL28B; PEG IFN; Ribavirin; Short treatment; Wk4 R

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

DOSE RESPONSE; DRUG EFFICACY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEREDITY; HUMAN; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERLEUKINS; PATIENT SELECTION; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78650096166     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02357.x     Document Type: Review

References (32)

1. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-5.
2. Mangia A., Santoro R., Minerva N., et al. Peginterferon alpha-2b and RBV for 12 vs 24 weeks in HCV genotype 2 and 3. N Engl J Med 2005; 35: 2609-17.
3. Von Wagner H, Huber H, Berg T, et al. PegInterferon alpha 2a (Pegasys) plus RBV (Copegus) for 16 or 24 weeks in patients with HCV genotpe 2 and 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.
4. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and RBV for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
5. Mecenate F, Pellicelli A, Barbaro G, et al. Short versus standard treatment with pegylated interferon alfa-2A plus ribavrin in patients with hepatitis C virus genotype 2 or 3: the Cleo trial. BMC Gastroenterol 2010; 10: 2-6.
6. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2. N Engl J Med 2007; 357: 124-34.
7. Lagging M, Langeland N, et al. for the NORdynamIC Study. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-45.
8. Yu ML, Dai CY, Huang JF, et al. A randomised study on PegInterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
9. Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic HCV genotype 2 or 3 infection. Hepatology 2009; 49: 358-63.
10. Slavenburg S, Weggelaar I, Van Oijen MGH, et al. Optimal length of antiviral therapy in patients with hepatitis C virus genotype 2 and 3: a meta-analysis. J Hepatol 2009; 50: S237.
11. Di Martino V, Richou C, Thevenot T, et al. Modulations of peg-interferon plus ribavirin duration according to HCV-genotye and virologic response at week 4 and week 12: metanalysis of RCTs with individual data. Hepatology 2008; 48 (Suppl.): 213.
12. Fried M, Hadziyannis SJ, Shiffman M, et al. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008; 48 (Suppl. 2): S5.
13. Ferenci P, Fried M, Shiffman M, et al. Predicting sustained responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425-33.
14. Diago M, Shiffmann M, Bronowicki J, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of pegInterferon alfa-2a (40 KD) plus ribavirin. Hepatology 2010; 51: 1897-903.
15. De Compadri P, Koleva D, Mangia A, Motterlini N, Garattini L. Cost minimization analysis of 12 or 24 weeks of peginterferon alfa-2b+ribavirin for hepatitis C virus. J Med Econ 2008; 11: 151-63.
16. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404.
17. Pedersen C, Alsio A, Lagging M, et al. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. J Viral Hep 2010. [Epub ahead of print].
18. McHutchison JG, Lawitz EJ, Muir AJ, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
19. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
20. Suppiah V, Moldovan M, Ahlenstiel G, et al. ILB is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
21. Tanaka Y, Sugyama M, Kurosaki M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genetics 2009; 41: 1105-9.
22. Conjeevaram HS, Fried MW, Jefers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7.
23. Muir AJ, Bernstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin fort he treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71.
24. Mangia A, Thompson A, Santoro R, et al. Predictive role of an IL28B polymorphism on SVR and RVR in patients with chronic genotype 2/3 HCV infection. J Hepatol 2010; 52: S56.
25. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure- a genome-wide association study. Gastroenetrology 2010; 138: 1338-45.
26. McCarthy JJ, Thompson A, Suchindran S, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
27. Tarantino G, Craxì A. Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotype 2 and 3: a review. Liv Int 2009; 29: 9-14.
28. Sanchéz-Tapias J, Diago M, Escartin P, et al. Peginterferon alfa 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
29. Willems B, Hadziyanni SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response. J Hepatol 2007; 46 (Suppl. 1): S6.
30. Mangia A, Bandiera F, Montalto G, et al. Individualized treatment with combination of Peg-Interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol 2010. [Epub ahead of print].
31. Jacobson IM, Brown RS Jr, Freilich BWIN-R study group et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-81.
32. Mangia A, Dalgard O, Verbaan H, et al. Ribavirin dosage in HCV genotypes 2 and 3 patients completing short therapy with peg-interferon alfa-2b and ribavirin. Aliment Pharmacol 2010; 1217: 4120-6.